Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3908
Name lung non-small cell carcinoma
Definition A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA act mut Pictilisib lung non-small cell carcinoma sensitive detail...
Unknown unknown XL147 lung non-small cell carcinoma not applicable detail...
Unknown unknown BMS-690514 lung non-small cell carcinoma not applicable detail...
ERBB2 mutant Neratinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Carboplatin + Paclitaxel + Ramucirumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Axitinib + Radiotherapy lung non-small cell carcinoma not applicable detail...
BRAF Y472C Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF G466V Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Dabrafenib lung non-small cell carcinoma sensitive detail...
ALK fusion ALK S1206Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown Adavosertib lung non-small cell carcinoma not applicable detail...
Unknown unknown Temsirolimus lung non-small cell carcinoma not applicable detail...
Unknown unknown Vandetanib lung non-small cell carcinoma not applicable detail...
PIK3CA E545K Copanlisib + Paclitaxel lung non-small cell carcinoma sensitive detail...
RET act mut Ponatinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Docetaxel + Ramucirumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Erlotinib + Everolimus lung non-small cell carcinoma not applicable detail...
Unknown unknown Pemetrexed Disodium + Sirolimus lung non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Lenvatinib + Paclitaxel lung non-small cell carcinoma not applicable detail...
Unknown unknown Merestinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Abemaciclib lung non-small cell carcinoma not applicable detail...
ALK rearrange SRC pos Ceritinib + Saracatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Belizatinib lung non-small cell carcinoma no benefit detail...
Unknown unknown Ficlatuzumab + Gefitinib lung non-small cell carcinoma not applicable detail...
ALK positive Ensartinib lung non-small cell carcinoma sensitive detail...
DDR2 act mut Lucitanib lung non-small cell carcinoma sensitive detail...
PDGFRA amp Sunitinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Bevacizumab + Carboplatin + Paclitaxel lung non-small cell carcinoma not applicable detail...
EML4 - ALK ALK G1269A Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1269A Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Ceritinib lung non-small cell carcinoma sensitive detail...
Unknown unknown A-1331852 + Docetaxel lung non-small cell carcinoma not applicable detail...
EML4 - ALK Ensartinib + Sirolimus lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R Ceritinib lung non-small cell carcinoma resistant detail...
Unknown unknown Alisertib lung non-small cell carcinoma not applicable detail...
PTPN11 act mut Refametinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK V1180L Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Lorlatinib lung non-small cell carcinoma sensitive detail...
PIK3CA mutant PWT33597 lung non-small cell carcinoma sensitive detail...
ALK rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
ERBB2 mutant AV-412 lung non-small cell carcinoma sensitive detail...
CDKN2A loss Palbociclib lung non-small cell carcinoma sensitive detail...
ALK fusion Alectinib lung non-small cell carcinoma sensitive detail...
ALK fusion Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Ceritinib lung non-small cell carcinoma conflicting detail...
NRAS Q61K Gedatolisib lung non-small cell carcinoma decreased response detail...
STK11 mutant Gedatolisib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Lorlatinib lung non-small cell carcinoma sensitive detail...
Unknown unknown BMS-906024 lung non-small cell carcinoma not applicable detail...
ALK rearrange Ceritinib + Crizotinib lung non-small cell carcinoma sensitive detail...
ALK mut ALK rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK V1180L Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK V1180L Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Brigatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Alectinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ensartinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Everolimus lung non-small cell carcinoma not applicable detail...
Unknown unknown Cediranib + Cisplatin + Gemcitabine lung non-small cell carcinoma not applicable detail...
Unknown unknown AXL1717 lung non-small cell carcinoma not applicable detail...
Unknown unknown XL228 lung non-small cell carcinoma not applicable detail...
Unknown unknown Conatumumab + Ganitumab lung non-small cell carcinoma not applicable detail...
EML4 - ALK TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G469A TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAE226 lung non-small cell carcinoma sensitive detail...
SRC amp Derazantinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Debio 1347 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Alectinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Trametinib + TW-37 lung non-small cell carcinoma sensitive detail...
BRAF V600E TW-37 + Vemurafenib lung non-small cell carcinoma sensitive detail...
Unknown unknown SH-1242 lung non-small cell carcinoma not applicable detail...
Unknown unknown PRN1371 lung non-small cell carcinoma not applicable detail...
Unknown unknown Docetaxel + Plinabulin lung non-small cell carcinoma not applicable detail...
BRAF L485_P490delinsY LY3009120 lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Trametinib lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Vemurafenib lung non-small cell carcinoma resistant detail...
ROS1 rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
Unknown unknown TVB-2640 lung non-small cell carcinoma not applicable detail...
EML4 - ALK ALK I1171S Alectinib lung non-small cell carcinoma predicted - resistant detail...
ATM loss AZD6738 + Cisplatin lung non-small cell carcinoma sensitive detail...
EML4 - ALK Entrectinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Luminespib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK C1156Y ALK L1198F Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown ST7612AA1 lung non-small cell carcinoma not applicable detail...
KDR amp Vandetanib lung non-small cell carcinoma no benefit detail...
Unknown unknown Ascrinvacumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Afatinib + Nimotuzumab lung non-small cell carcinoma not applicable detail...
CDH1 over exp BI2536 lung non-small cell carcinoma resistant detail...
CDH1 over exp Volasertib lung non-small cell carcinoma resistant detail...
EML4 - ALK Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib lung non-small cell carcinoma sensitive detail...
CBLC over exp N/A lung non-small cell carcinoma not applicable detail...
Unknown unknown Nivolumab lung non-small cell carcinoma not applicable detail...
Unknown unknown BAY1161909 + Paclitaxel lung non-small cell carcinoma not applicable detail...
Unknown unknown BAY1217389 + Paclitaxel lung non-small cell carcinoma not applicable detail...
ALK fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R Lorlatinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp AZD4547 lung non-small cell carcinoma sensitive detail...
ERBB2 amp Afatinib lung non-small cell carcinoma sensitive detail...
ERBB2 G776delinsVC Afatinib lung non-small cell carcinoma conflicting detail...
ERBB2 G776delinsVC Gefitinib lung non-small cell carcinoma resistant detail...
RET fusion Vandetanib lung non-small cell carcinoma sensitive detail...
ALK neg ROS1 rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
EZH2 over exp JQEZ5 lung non-small cell carcinoma sensitive detail...
ALK mutant Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
Unknown unknown Vantictumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Sorafenib lung non-small cell carcinoma no benefit detail...
Unknown unknown LY3164530 lung non-small cell carcinoma not applicable detail...
BRAF L485Y GDC0879 lung non-small cell carcinoma resistant detail...
BRAF wild-type GDC0879 lung non-small cell carcinoma resistant detail...
BRAF L597V NRAS Q61K AZ628 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K PLX7904 lung non-small cell carcinoma decreased response detail...
BRAF L597V NRAS Q61K Vemurafenib lung non-small cell carcinoma decreased response detail...
BRAF G466V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF L597V NRAS Q61K Dabrafenib lung non-small cell carcinoma decreased response detail...
NRAS Q61K Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Everolimus + Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Sorafenib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Regorafenib lung non-small cell carcinoma sensitive detail...
Unknown unknown Bavituximab + Docetaxel lung non-small cell carcinoma no benefit detail...
PIK3CA mutant PF-04691502 lung non-small cell carcinoma sensitive detail...
FGFR1 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR2 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR3 amp PRN1371 lung non-small cell carcinoma sensitive detail...
ALK rearrange Nivolumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Pembrolizumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Durvalumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Atezolizumab lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO4987655 lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung non-small cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung non-small cell carcinoma no benefit detail...
Unknown unknown RXDX-105 lung non-small cell carcinoma not applicable detail...
Unknown unknown Axitinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Lenvatinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Docetaxel + Nintedanib lung non-small cell carcinoma not applicable detail...
ALK E1210K ALK rearrange Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange MAP2K1 K57N Ceritinib + Selumetinib lung non-small cell carcinoma sensitive detail...
Unknown unknown AZD8055 + SBI-0206965 lung non-small cell carcinoma not applicable detail...
Unknown unknown Sapanisertib + SBI-0206965 lung non-small cell carcinoma not applicable detail...
Unknown unknown SBI-0206965 + Sirolimus lung non-small cell carcinoma not applicable detail...
PIK3CA G118D LY3023414 lung non-small cell carcinoma sensitive detail...
Unknown unknown Atezolizumab lung non-small cell carcinoma not applicable detail...
EML4 - ALK Afatinib + Alectinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp E7090 lung non-small cell carcinoma sensitive detail...
FGFR1 amp NGI-1 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK Brigatinib lung non-small cell carcinoma sensitive detail...
Unknown unknown NU7441 + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown Gemcitabine + SRA737 lung non-small cell carcinoma not applicable detail...
Unknown unknown Ganetespib + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown Dasatinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Ganetespib + Paclitaxel + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown Cetuximab + Cisplatin + Vinorelbine lung non-small cell carcinoma no benefit detail...
BRAF G469A Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF mutant Dabrafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469V Sorafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A Vemurafenib lung non-small cell carcinoma resistant detail...
BRAF G469A Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Trametinib + Vemurafenib lung non-small cell carcinoma conflicting detail...
ROS1 rearrange NPS-1034 lung non-small cell carcinoma sensitive detail...
Unknown unknown Pimitespib + Radiotherapy lung non-small cell carcinoma not applicable detail...
STK11 inact mut Trametinib lung non-small cell carcinoma sensitive detail...
STK11 Q37* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 E199* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 W332* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 dec exp Trametinib lung non-small cell carcinoma sensitive detail...
STK11 K48fs Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Antroquinonol lung non-small cell carcinoma not applicable detail...
Unknown unknown Sunitinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Regorafenib lung non-small cell carcinoma not applicable detail...
Unknown unknown Aflibercept + Docetaxel lung non-small cell carcinoma not applicable detail...
Unknown unknown Pazopanib lung non-small cell carcinoma not applicable detail...
Unknown unknown Metformin lung non-small cell carcinoma not applicable detail...
ERBB2 mutant Pyrotinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion DS6051b lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 mutant Trastuzumab + Vinorelbine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Afatinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 A775_G776insYVMA PIK3CA R425L Trastuzumab lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown TMU-35435 lung non-small cell carcinoma not applicable detail...
Unknown unknown Decitabine + TMU-35435 lung non-small cell carcinoma not applicable detail...
Unknown unknown Chiauranib lung non-small cell carcinoma not applicable detail...
Unknown unknown INCB059872 lung non-small cell carcinoma not applicable detail...
ALK positive Entrectinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Cabozantinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Cabozantinib + Erlotinib lung non-small cell carcinoma not applicable detail...
RET rearrange Alectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171N ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK G1202R ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange Entrectinib lung non-small cell carcinoma sensitive detail...
STK11 E57fs Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown DCBCI0901 lung non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Veliparib lung non-small cell carcinoma not applicable detail...
Unknown unknown Ro 31-8220 lung non-small cell carcinoma not applicable detail...
EML4 - ALK ALK F1245C Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1245C Ceritinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Docetaxel + Trametinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Pemetrexed Disodium + Trametinib lung non-small cell carcinoma not applicable detail...
Unknown unknown SIM-89 lung non-small cell carcinoma not applicable detail...
RET rearrange Cabozantinib lung non-small cell carcinoma sensitive detail...
RET rearrange Vandetanib lung non-small cell carcinoma sensitive detail...
RET rearrange Sunitinib lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Zenocutuzumab lung non-small cell carcinoma not applicable detail...
Unknown unknown CPI-444 lung non-small cell carcinoma not applicable detail...
Unknown unknown Atezolizumab + CPI-444 lung non-small cell carcinoma not applicable detail...
Unknown unknown Pimitespib lung non-small cell carcinoma not applicable detail...
FGFR3 - TACC3 Erdafitinib lung non-small cell carcinoma sensitive detail...
RET rearrange RXDX-105 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Cisplatin + Gemcitabine + Metformin lung non-small cell carcinoma not applicable detail...
ROS1 rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
PIK3CA H1047X Taselisib lung non-small cell carcinoma sensitive detail...
FGFR1 amp GSK3052230 lung non-small cell carcinoma sensitive detail...
Unknown unknown LY2874455 lung non-small cell carcinoma not applicable detail...
BRAF G466V Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G466V NRAS Q61K Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Navitoclax + TAK-901 lung non-small cell carcinoma not applicable detail...
Unknown unknown Barasertib + Navitoclax lung non-small cell carcinoma not applicable detail...
BRAF mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466V Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown CCT244747 + Gemcitabine lung non-small cell carcinoma not applicable detail...
Unknown unknown LY2603618 + Pemetrexed Disodium lung non-small cell carcinoma no benefit detail...
NRAS mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
STK11 mutant unspecified PD-1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp NRAS amp Infigratinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Trametinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp NRAS over exp Infigratinib lung non-small cell carcinoma decreased response detail...
FGFR1 amp NRAS over exp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
Unknown unknown BJ-1301 lung non-small cell carcinoma not applicable detail...
EML4 - ALK Crizotinib + Filgotinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174V Alectinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171S ALK F1174V Alectinib lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel lung non-small cell carcinoma no benefit detail...
ALK rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1174V Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1152R Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1269A Crizotinib lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown Cisplatin + PJ34 lung non-small cell carcinoma not applicable detail...
ALK T1151dup ALK G1269A ALK rearrange Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK amp ALK rearrange Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1202R Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK CEP-28122 lung non-small cell carcinoma sensitive detail...
ALK negative CEP-28122 lung non-small cell carcinoma resistant detail...
ALK L1196M ALK rearrange Crizotinib lung non-small cell carcinoma resistant detail...
ALK S1206Y ALK rearrange Crizotinib lung non-small cell carcinoma resistant detail...
ALK C1156Y ALK rearrange Crizotinib lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown Pembrolizumab lung non-small cell carcinoma not applicable detail...
SRC positive AC-93253 iodide lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Durvalumab lung non-small cell carcinoma not applicable detail...
ROS1 rearrange Alectinib lung non-small cell carcinoma no benefit detail...
ERBB2 mutant Ado-trastuzumab emtansine lung non-small cell carcinoma sensitive detail...
ALK rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
ERBB2 G776_V777insVGC Neratinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 G776delinsVC Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 G778_P780dup Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 L755A Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 L755P Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 L755S Neratinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 L786V Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 S310F Neratinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 V659E Neratinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Neratinib lung non-small cell carcinoma no benefit detail...
ERBB2 exon 20 ins Neratinib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK F1174V ALK G1202R Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK F1174C Ceritinib lung non-small cell carcinoma resistant detail...
Unknown unknown Panobinostat + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Vorinostat lung non-small cell carcinoma not applicable detail...
Unknown unknown Cisplatin + Etoposide + Panobinostat + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown Belinostat + Carboplatin + Paclitaxel lung non-small cell carcinoma not applicable detail...
Unknown unknown Gemcitabine + Milciclib lung non-small cell carcinoma not applicable detail...
BRAF act mut RAF709 lung non-small cell carcinoma sensitive detail...
Unknown unknown BPI-9016M lung non-small cell carcinoma not applicable detail...
ALK I1171N ALK L1198F ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
ALK I1171N ALK D1203N ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
ALK C1156Y ALK L1198F ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
ALK L1196M ALK G1202R ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
ALK G1202R ALK L1204V ALK G1269A ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
ALK D1203N ALK E1210K ALK G1269A ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
Unknown unknown Pegilodecakin + Pembrolizumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Nivolumab + Pegilodecakin lung non-small cell carcinoma not applicable detail...
RET fusion Selpercatinib lung non-small cell carcinoma sensitive detail...
Unknown unknown ALT-803 + Nivolumab lung non-small cell carcinoma not applicable detail...
Unknown unknown Paclitaxel + Vistusertib lung non-small cell carcinoma not applicable detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK E1210K Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK S1206C ALK E1210K Brigatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK F1174L ALK L1198V Brigatinib lung non-small cell carcinoma resistant detail...
ROS1 fusion KIT D816G Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK NOTCH1 D1533A Ceritinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK NOTCH1 D1538A Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion KDR amp KIT amp PDGFRA amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ERBB2 amp FGFR3 amp RET amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK FGFR1 amp Brigatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK GNAS amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK HRAS amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK DDR2 amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
Unknown unknown BIO-11006 lung non-small cell carcinoma not applicable detail...
PTPN11 T253M PTPN11 Q257L Selumetinib + SHP099 lung non-small cell carcinoma resistant detail...
BRAF G469A Encorafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Dabrafenib lung non-small cell carcinoma sensitive detail...
ERBB2 Y772_A775dup Afatinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Dacomitinib lung non-small cell carcinoma no benefit detail...
ERBB2 Y772_A775dup Erlotinib lung non-small cell carcinoma no benefit detail...
ERBB2 Y772_A775dup Poziotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Dacomitinib lung non-small cell carcinoma no benefit detail...
ERBB2 G776delinsVC Erlotinib lung non-small cell carcinoma no benefit detail...
ERBB2 G776delinsVC Lapatinib lung non-small cell carcinoma no benefit detail...
ERBB2 G776delinsVC Poziotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G778_P780dup Afatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171N ALK rearrange Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171T ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK V1180L ALK rearrange Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK V1180L ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171T ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK V1180L ALK L1196M ALK G1202R ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK D1203N ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
BRAF D594N RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581D RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Abemaciclib + Pemetrexed Disodium lung non-small cell carcinoma not applicable detail...
Unknown unknown Abemaciclib + Gemcitabine lung non-small cell carcinoma not applicable detail...
Unknown unknown Abemaciclib + Ramucirumab lung non-small cell carcinoma not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 act mut Pertuzumab + Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Bevacizumab lung non-small cell carcinoma no benefit detail...
RET rearrange Ponatinib lung non-small cell carcinoma no benefit detail...
FGFR1 V561M AZD4547 lung non-small cell carcinoma resistant detail...
Unknown unknown Dostarlimab + TSR-033 lung non-small cell carcinoma not applicable detail...
STK11 mutant unspecified PD-L1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK G1269A ALK rearrange Lorlatinib lung non-small cell carcinoma resistant detail...
CDKN2A negative Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
CDKN2A negative Everolimus + Palbociclib lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + Sirolimus lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + PF-04691502 lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R KIT amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK WX-0593 lung non-small cell carcinoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E/K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
ERBB2 mutant Trastuzumab lung non-small cell carcinoma no benefit detail...
ERBB2 mutant Afatinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Brigatinib lung non-small cell carcinoma no benefit detail...
Unknown unknown Sabatolimab lung non-small cell carcinoma not applicable detail...
Unknown unknown Sabatolimab + Spartalizumab lung non-small cell carcinoma not applicable detail...
ERBB2 exon20 Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
CDKN2A mutant Palbociclib lung non-small cell carcinoma sensitive detail...
ALK fusion Crizotinib lung non-small cell carcinoma sensitive detail...
ALK fusion Ceritinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK MTI-31 lung non-small cell carcinoma sensitive detail...
Unknown unknown LYC-55716 lung non-small cell carcinoma not applicable detail...
PIK3CA E545K ROS1 rearrange Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 act mut Camrelizumab lung non-small cell carcinoma decreased response detail...
ERBB2 act mut Pembrolizumab lung non-small cell carcinoma decreased response detail...
ERBB2 act mut Nivolumab lung non-small cell carcinoma decreased response detail...
ERBB2 act mut Atezolizumab lung non-small cell carcinoma decreased response detail...
PDGFRA N848K Imatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK rearrange Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK G1202R ALK rearrange Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171X ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171X ALK rearrange Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171X ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171X ALK rearrange Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK L1196M ALK rearrange Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK L1196M ALK rearrange Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK L1196M ALK rearrange Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK L1196M ALK rearrange Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK L1196M ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK G1202R ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK D1203N ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK F1174C ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK F1174L ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK I1171X ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 positive Entrectinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Entrectinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Emibetuzumab + Ramucirumab lung non-small cell carcinoma not applicable detail...
EML4 - ALK ALK E1303K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ensartinib lung non-small cell carcinoma sensitive detail...
Unknown unknown Mogamulizumab + Nivolumab lung non-small cell carcinoma not applicable detail...
ALK rearrange PLB1003 lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown AZD7648 + Radiotherapy lung non-small cell carcinoma not applicable detail...
Unknown unknown AZD7648 lung non-small cell carcinoma not applicable detail...
ATM del AZD7648 + Olaparib lung non-small cell carcinoma sensitive detail...
ATM del AZD7648 lung non-small cell carcinoma sensitive detail...
ALK F1174C ALK G1202R ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK F1174L ALK G1202R ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK T1151M ALK G1202R ALK rearrange Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 Y772_A775dup Ado-trastuzumab emtansine + Poziotinib lung non-small cell carcinoma sensitive detail...
ERBB2 G778_P780dup Poziotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 L755P Poziotinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
ALK C1156Y ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174L ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1196M ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171T ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171S ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK amp ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp eFT226 lung non-small cell carcinoma sensitive detail...
ATM del Olaparib lung non-small cell carcinoma sensitive detail...
Unknown unknown Atezolizumab + Cobimetinib lung non-small cell carcinoma not applicable detail...
Unknown unknown DNIB0600A lung non-small cell carcinoma not applicable detail...
Unknown unknown GSK3368715 lung non-small cell carcinoma not applicable detail...
BRAF V600X Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600D Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600M Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600K Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581S Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601E Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601N Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G466A Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G469V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G596R Vemurafenib lung non-small cell carcinoma no benefit detail...
Unknown unknown Lenvatinib + Pembrolizumab lung non-small cell carcinoma not applicable detail...
PIK3CA mutant Sulindac lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Defactinib lung non-small cell carcinoma not applicable detail...
Unknown unknown Emibetuzumab + Erlotinib lung non-small cell carcinoma not applicable detail...
PIK3CA act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
NRAS act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
BRAF act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37F Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37C Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 D32V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 G34V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 T41I Osimertinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
ERBB2 A775_G776insYVMA Pyrotinib lung non-small cell carcinoma sensitive detail...
ERBB2 A775_G776insYVMA Afatinib lung non-small cell carcinoma sensitive detail...
ERBB2 A775_G776insYVMA Ado-trastuzumab emtansine lung non-small cell carcinoma sensitive detail...
ERBB2 P780_Y781insGSP Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776C Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 L755P Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776delinsIC Pyrotinib lung non-small cell carcinoma no benefit detail...
Unknown unknown SGN-CD228A lung non-small cell carcinoma not applicable detail...
Unknown unknown unspecified PD-1 antibody lung non-small cell carcinoma not applicable detail...
Unknown unknown unspecified PD-L1 antibody lung non-small cell carcinoma not applicable detail...
ARID1A mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
PIK3CA amp Sulindac lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown ADXS-503 lung non-small cell carcinoma not applicable detail...
Unknown unknown ADXS-503 + Pembrolizumab lung non-small cell carcinoma not applicable detail...
Unknown unknown HS-110 + Nivolumab lung non-small cell carcinoma not applicable detail...
Unknown unknown MGC018 lung non-small cell carcinoma not applicable detail...
ERBB2 V659E Icotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 V659E Capecitabine + Lapatinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 V659E Afatinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 V659E Afatinib + Rivoceranib lung non-small cell carcinoma no benefit detail...
ERBB2 V659E Anlotinib lung non-small cell carcinoma no benefit detail...
ERBB2 over exp Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776_V777insVC ERBB2 over exp Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 amp ERBB2 over exp Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 amp ERBB2 over exp ERBB2 rearrange Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Trastuzumab + Vinorelbine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Carboplatin + Paclitaxel + Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 exon 20 ins Docetaxel + Trastuzumab lung non-small cell carcinoma predicted - sensitive detail...
RET fusion BLU-667 lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange Selpercatinib lung non-small cell carcinoma sensitive detail...
Unknown unknown ALX148 + Pembrolizumab lung non-small cell carcinoma not applicable detail...
ROS1 rearrange DS6051b lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Carboplatin + MEDI-575 + Paclitaxel lung non-small cell carcinoma not applicable detail...
ERBB2 G778_P780dup Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 V777L Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 act mut Pyrotinib lung non-small cell carcinoma predicted - sensitive detail...
ALK mutant Belizatinib lung non-small cell carcinoma no benefit detail...
ALK amp Belizatinib lung non-small cell carcinoma no benefit detail...
Unknown unknown Docetaxel + Pembrolizumab lung non-small cell carcinoma not applicable detail...
STK11 loss Vistusertib lung non-small cell carcinoma no benefit detail...
FGFR2 - MBIP AZD4547 lung non-small cell carcinoma predicted - sensitive detail...
FGFR2 V514L AZD4547 lung non-small cell carcinoma no benefit detail...
FGFR3 P573S AZD4547 lung non-small cell carcinoma no benefit detail...
FGFR3 S756P AZD4547 lung non-small cell carcinoma no benefit detail...
ERBB2 amp Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Ado-trastuzumab emtansine lung non-small cell carcinoma no benefit detail...
ERBB2 P780_Y781insGSP Ado-trastuzumab emtansine lung non-small cell carcinoma predicted - sensitive detail...
Unknown unknown Anlotinib lung non-small cell carcinoma not applicable detail...
ERBB2 exon20 Afatinib lung non-small cell carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00150657 Phase II Bevacizumab + Carboplatin + Gemcitabine Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Unknown status
NCT00254319 Phase II Carboplatin Bevacizumab + Pemetrexed Disodium Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Unknown status
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed
NCT00547105 Phase II Erlotinib Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer Completed
NCT00569296 Phase I Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer Terminated
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Active, not recruiting
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Recruiting
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT00932451 Phase II Crizotinib An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed
NCT00950365 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status
NCT00975767 Phase Ib/II Docetaxel + Glesatinib Erlotinib + Glesatinib A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Terminated
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed
NCT00979212 Phase II Panitumumab Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) Active, not recruiting
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated
NCT00997334 Phase II Erlotinib Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC Completed
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed
NCT01059552 Phase I Vorinostat Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Completed
NCT01061788 Phase I Everolimus + Ganitumab + Panitumumab A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer Completed
NCT01107626 Phase III Pemetrexed Disodium Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01179269 Phase II Paclitaxel + Pazopanib Stage IIIB/IV Non-Small Cell Lung Cancer Withdrawn
NCT01210378 Phase II Nitroglycerin Nitroglycerin in Non-small Cell Lung Cancer Terminated
NCT01233687 Phase Ib/II Rilotumumab Erlotinib AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Completed
NCT01248247 Phase I Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Active, not recruiting
NCT01263782 Phase II Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Completed
NCT01288430 Phase I DS-2248 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed
NCT01336634 Phase II Dabrafenib Dabrafenib + Trametinib Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Active, not recruiting
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Disodium Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed
NCT01351415 Phase III Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Completed
NCT01383148 Phase Ib/II MVA-MUC1-IL2 vaccine Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated
NCT01386385 Phase Ib/II Carboplatin + Paclitaxel Carboplatin + Etoposide + Veliparib Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Active, not recruiting
NCT01455389 Phase Ib/II DOTAP:chol-Fus1 Erlotinib Diphenhydramine Dexamethasone FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer Active, not recruiting
NCT01456325 Phase III Erlotinib Onartuzumab A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Completed
NCT01465802 Phase II Dacomitinib Alclometasone Doxycycline Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed
NCT01487265 Phase II Buparlisib + Erlotinib Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib Completed
NCT01493843 Phase II Carboplatin Pictilisib Bevacizumab Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer Completed
NCT01514864 Phase II Dasatinib Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Terminated
NCT01526928 Phase Ib/II Rociletinib Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Terminated
NCT01532089 Phase II Bevacizumab Bevacizumab + Erlotinib Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Active, not recruiting
NCT01537744 Phase I Azacitidine + Romidepsin A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Completed
NCT01545947 Phase I Azacitidine + Onatasertib Erlotinib + Onatasertib Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer Completed
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Disodium Afatinib With CT and RT for EGFR-Mutant NSCLC Recruiting
NCT01573702 Phase II Erlotinib Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Active, not recruiting
NCT01574729 Phase II rAD-p53 Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma Unknown status
NCT01578551 Phase II Metformin Carboplatin + Paclitaxel Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01620190 Phase II Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer Active, not recruiting
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01628471 Phase Ib/II Decitabine + Genistein MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer Completed
NCT01630733 Phase III Docetaxel Custirsen + Docetaxel A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Unknown status
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting
NCT01646125 Phase II Docetaxel Luminespib Pemetrexed Disodium An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated
NCT01647711 Phase I Afatinib A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations Completed
NCT01649284 Phase I Afatinib Afatinib Expanded Access Program Approved for marketing
NCT01649947 Phase II Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel Carboplatin + Hydroxychloroquine + Paclitaxel Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II Completed
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed
NCT01664754 Phase I Pemetrexed Disodium Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Completed
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Disodium Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed
NCT01708993 Phase II Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed
NCT01712217 Phase Ib/II Crizotinib Onalespib A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Completed
NCT01717482 Phase II Metformin Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer Terminated
NCT01720836 Phase Ib/II MUC1 peptide-Poly-ICLC vaccine Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer Recruiting
NCT01723800 Phase I Buparlisib + Carboplatin + Pemetrexed Disodium PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Completed
NCT01725165 Phase II Oligometastatic Disease Active, not recruiting
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed
NCT01746251 Phase II Afatinib Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Active, not recruiting
NCT01750281 Phase II Docetaxel Docetaxel + Selumetinib Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Active, not recruiting
NCT01752400 Phase II Luminespib AUY922 for Advanced ALK-positive NSCLC Completed
NCT01769391 Phase II Necitumumab Carboplatin + Paclitaxel A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed
NCT01772797 Phase I Ceritinib Luminespib Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Completed
NCT01783197 Phase I Selumetinib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Completed
NCT01784640 Phase I Luminespib + Pemetrexed Disodium Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Completed
NCT01788566 Phase II Cisplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer Completed
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated
NCT01801111 Phase II Erlotinib Alectinib A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment Completed
NCT01802632 Phase Ib/II Osimertinib AZD9291 First Time In Patients Ascending Dose Study Active, not recruiting
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed
NCT01813734 Phase II Ponatinib Ponatinib in Advanced NSCLC w/ RET Translocations Completed
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed
NCT01822496 Phase II Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated
NCT01828112 Phase III Docetaxel Pemetrexed Disodium Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting
NCT01829217 Phase II Sunitinib Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01833143 Phase II Bortezomib Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Completed
NCT01837329 Phase I Tetrathiomolybdate Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Completed
NCT01839955 Phase Ib/II Erlotinib + Quinacrine Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer Completed
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT01851369 Phase Ib/II Temozolomide + TRC102 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Recruiting
NCT01854034 Phase II Luminespib Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Completed
NCT01857271 Phase II Erlotinib Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated
NCT01858389 Phase II Dacomitinib A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Completed
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Active, not recruiting
NCT01866410 Phase II Cabozantinib + Erlotinib Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer Completed
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT01871805 Phase Ib/II Alectinib A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Completed
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed
NCT01887886 Phase III Erlotinib + Onartuzumab A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation Completed
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed
NCT01900652 Phase II Emibetuzumab + Erlotinib Emibetuzumab A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants Completed
NCT01903993 Phase II Atezolizumab A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" Completed
NCT01911325 Phase Ib/II Buparlisib Docetaxel Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Terminated
NCT01911507 Phase I Capmatinib + Erlotinib INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting
NCT01912625 Phase I Carboplatin + Paclitaxel + Trametinib Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed
NCT01928160 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn
NCT01928576 Phase II Nivolumab Entinostat Azacitidine Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. Recruiting
NCT01933932 Phase III Docetaxel + Selumetinib Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) Active, not recruiting
NCT01935947 Phase II Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Terminated
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed
NCT01947608 Phase I Ceritinib Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC Available
NCT01951690 Phase II Defactinib Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Completed
NCT01957007 Phase I Docetaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Completed
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01967095 Phase I Erlotinib Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01970865 Phase II Lorlatinib Crizotinib A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Active, not recruiting
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT01993810 Phase III Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Recruiting
NCT01998126 Phase I Erlotinib + Ipilimumab Crizotinib + Ipilimumab Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed
NCT02000947 Phase Ib/II Durvalumab + Tremelimumab A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Completed
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02013219 Phase I Alectinib + Atezolizumab Atezolizumab + Erlotinib A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer Completed
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02019979 Phase II Metformin Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) Terminated
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Active, not recruiting
NCT02031458 Phase II Atezolizumab A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH Completed
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT02039674 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Disodium Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Active, not recruiting
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Active, not recruiting
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed
NCT02044601 Phase Ib/II Carboplatin + Onartuzumab + Paclitaxel Carboplatin + Erlotinib + Onartuzumab + Paclitaxel Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) Withdrawn
NCT02045446 Phase II Bevacizumab + Erlotinib Docetaxel + Gemcitabine Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02047344 Phase II Antroquinonol Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Completed
NCT02066636 Phase III Nivolumab A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) Active, not recruiting
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed
NCT02075840 Phase III Alectinib Crizotinib A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) Active, not recruiting
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed
NCT02080078 Phase I Erlotinib + Theophylline A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Terminated
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Completed
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated
NCT02087241 Phase II Adavosertib Carboplatin + Pemetrexed Disodium Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Terminated
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting
NCT02088112 Phase I Durvalumab + Gefitinib MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). Active, not recruiting
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Active, not recruiting
NCT02094573 Phase II Brigatinib A Phase 2, Multicenter, Randomized Study of AP26113 Completed
NCT02106546 Phase III Veliparib Carboplatin + Paclitaxel Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Completed
NCT02108964 Phase Ib/II Nazartinib A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Active, not recruiting
NCT02109016 Phase II Lucitanib A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer Terminated
NCT02113813 Phase I Naquotinib A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Completed
NCT02115464 Phase II Metformin Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Terminated
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Terminated
NCT02119650 Phase II Cisplatin + Pemetrexed Disodium + Ruxolitinib Cisplatin + Pemetrexed Disodium Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Terminated
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Active, not recruiting
NCT02132598 Phase II Cabozantinib Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Completed
NCT02133196 Phase II Aldesleukin + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Recruiting
NCT02134015 Phase III Erlotinib Erlotinib + Patritumab Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Terminated
NCT02134886 Phase I Erlotinib Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection Terminated
NCT02134912 Phase II Crizotinib + Pemetrexed Disodium Pemetrexed Disodium S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Active, not recruiting
NCT02143466 Phase I Osimertinib + Savolitinib Savolitinib Osimertinib + Selumetinib Durvalumab + Osimertinib AZD9291 in Combination With Ascending Doses of Novel Therapeutics Active, not recruiting
NCT02147990 Phase II Rociletinib TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) Terminated
NCT02151981 Phase III Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Osimertinib AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) Active, not recruiting
NCT02152631 Phase III Erlotinib Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Active, not recruiting
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed
NCT02157883 Phase I Osimertinib Itraconazole + Osimertinib Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Active, not recruiting
NCT02163733 Phase I Osimertinib Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Active, not recruiting
NCT02179671 Phase II Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
NCT02186301 Phase II Rociletinib Erlotinib TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Terminated
NCT02186847 Phase II Metformin Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated
NCT02193282 Phase III Erlotinib Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Recruiting
NCT02194738 Phase I Nivolumab Crizotinib Erlotinib Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting
NCT02197234 Phase I Osimertinib + Simvastatin Simvastatin Osimertinib Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC Active, not recruiting
NCT02197247 Phase I Osimertinib + Rifampin Osimertinib Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC Active, not recruiting
NCT02201992 Phase III Crizotinib Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting
NCT02206763 Phase I Erlotinib + Momelotinib Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated
NCT02220894 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Active, not recruiting
NCT02221739 Phase II Ipilimumab Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed
NCT02225405 Phase I Cisplatin + Docetaxel + Nintedanib Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) Active, not recruiting
NCT02228369 Phase I Osimertinib AZD3759 Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) Active, not recruiting
NCT02250326 Phase II Azacitidine + Nab-paclitaxel Nab-paclitaxel Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer Active, not recruiting
NCT02257619 Phase II Docetaxel Itacitinib Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Terminated
NCT02258607 Phase I Momelotinib Momelotinib + Trametinib Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase Terminated
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02259582 Phase II Carboplatin + Pemetrexed Disodium Demcizumab A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Completed
NCT02259621 Phase II Nivolumab Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC Recruiting
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02264990 Phase III Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Completed
NCT02271139 Phase III Alectinib Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib No longer available
NCT02271906 Phase II Afatinib The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting Terminated
NCT02272413 Phase III Carboplatin + Paclitaxel Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Active, not recruiting
NCT02277457 Phase I Crizotinib Erlotinib Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations Withdrawn
NCT02279433 Phase I DS6051b A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Active, not recruiting
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed
NCT02289833 Phase II Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
NCT02292550 Phase Ib/II Ceritinib + Ribociclib Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Completed
NCT02296125 Phase III Erlotinib Osimertinib Gefitinib AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) Active, not recruiting
NCT02298153 Phase I Atezolizumab + Epacadostat A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Terminated
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT02299505 Phase I Ceritinib Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) Completed
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed
NCT02309892 Phase I Carboplatin + L-DOS47 + Pemetrexed Disodium A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC Completed
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02314364 Phase II A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC Recruiting
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Active, not recruiting
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02317016 Phase I Osimertinib Rosuvastatin Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer Completed
NCT02318368 Phase II Erlotinib Erlotinib + Ficlatuzumab A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label Terminated
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02321293 Phase I Erlotinib + Gefitinib A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC Unknown status
NCT02321501 Phase I Ceritinib + Everolimus Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02321540 Phase Ib/II Ibrutinib A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Active, not recruiting
NCT02322281 Phase III Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated
NCT02323126 Phase II Nazartinib + Nivolumab Capmatinib + Nivolumab Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer Recruiting
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02335944 Phase Ib/II Capmatinib + Nazartinib Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation. Active, not recruiting
NCT02336451 Phase II Ceritinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges Completed
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Disodium Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Completed
NCT02342353 Phase Ib/II Erlotinib + Pacritinib Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) Terminated
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Active, not recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02349633 Phase II Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) Completed
NCT02350764 Phase II Ipilimumab + Nivolumab Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs Recruiting
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Active, not recruiting
NCT02355431 Phase II Erlotinib Itacitinib INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Withdrawn
NCT02357836 Phase I Itraconazole Neoadjuvant Itraconazole in Non-small Cell Lung Cancer Completed
NCT02364609 Phase I Afatinib + Pembrolizumab Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Active, not recruiting
NCT02364999 Phase III Bevacizumab + Carboplatin + Paclitaxel A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC Completed
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02366143 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Active, not recruiting
NCT02367781 Phase III Atezolizumab Carboplatin + Nab-paclitaxel A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer Completed
NCT02367794 Phase III Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Active, not recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated
NCT02387216 Phase II Seribantumab Pemetrexed Disodium Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Completed
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed
NCT02392507 Phase II Carboplatin + Nab-paclitaxel + Necitumumab A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Completed
NCT02393625 Phase I Ceritinib + Nivolumab Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Active, not recruiting
NCT02395172 Phase III Avelumab Docetaxel Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Completed
NCT02400814 Phase I Atezolizumab MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Active, not recruiting
NCT02403193 Phase Ib/II PBF-509 + Spartalizumab PBF-509 Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) Active, not recruiting
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Suspended
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated
NCT02411448 Phase III Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) Active, not recruiting
NCT02412371 Phase II Veliparib Carboplatin + Paclitaxel A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer Terminated
NCT02414139 Phase II Capmatinib Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer Recruiting
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02422589 Phase I Warfarin Midazolam Ceritinib A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors Completed
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed
NCT02424617 Phase Ib/II Bemcentinib + Erlotinib A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Unknown status
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Active, not recruiting
NCT02438722 Phase II Afatinib Afatinib + Cetuximab S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Active, not recruiting
NCT02439450 Phase I HS-110 Nivolumab A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Active, not recruiting
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02448251 Phase I Abivertinib Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer Terminated
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Completed
NCT02450539 Phase II Abemaciclib Docetaxel A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Active, not recruiting
NCT02451852 Phase I Osimertinib AZD9291 US Expanded Access Program No longer available
NCT02451865 Phase I Binimetinib + Docetaxel Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer Withdrawn
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Completed
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC) Active, not recruiting
NCT02454842 Phase II TH-4000 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Terminated
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours Active, not recruiting
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02460367 Phase Ib/II Docetaxel + Indoximod Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Active, not recruiting
NCT02463994 Phase I Atezolizumab A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Completed
NCT02468661 Phase I Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Terminated
NCT02469701 Phase II Nivolumab BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease Terminated
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed
NCT02474355 Phase III Osimertinib Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Active, not recruiting
NCT02475382 Expanded access Nivolumab Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) No longer available
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02485652 Phase II Olmutinib Phase II Trial of HM61713 for the Treatment of ?2nd Line T790M Mutation Positive Adenocarcinoma of the Lung Active, not recruiting
NCT02486718 Phase III Atezolizumab Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer Active, not recruiting
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Active, not recruiting
NCT02492867 Phase 0 Durvalumab Carboplatin + Paclitaxel A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT02495636 Phase II Atezolizumab + Rasdegafusp alfa Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer Withdrawn
NCT02496663 Phase I Necitumumab + Osimertinib Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Recruiting
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Active, not recruiting
NCT02503722 Phase I Osimertinib + Sapanisertib Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer Active, not recruiting
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Active, not recruiting
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) Recruiting
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02511106 Phase III Osimertinib AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA) Active, not recruiting
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated
NCT02514174 FDA approved Afatinib Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Completed
NCT02516813 Phase I MSC2490484A Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Recruiting
NCT02520778 Phase I Navitoclax + Osimertinib Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT02521051 Phase Ib/II Bevacizumab Alectinib Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Recruiting
NCT02523469 Phase Ib/II ALT-803 + Nivolumab ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02525757 Phase II Atezolizumab Carboplatin + Paclitaxel MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed
NCT02535338 Phase Ib/II Erlotinib + Onalespib Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer Active, not recruiting
NCT02537561 Phase I Talazoparib Cisplatin + Gemcitabine Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02542293 Phase III Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE) Active, not recruiting
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02544633 Phase II Glesatinib Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET Completed
NCT02546986 Phase II Azacitidine Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting
NCT02547675 Phase I Rociletinib Rociletinib (CO-1686) USA Expanded Access Program No longer available
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Completed
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Recruiting
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Active, not recruiting
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Active, not recruiting
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Active, not recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) Active, not recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated
NCT02578680 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Active, not recruiting
NCT02580708 Phase Ib/II Trametinib Rociletinib A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Terminated
NCT02581787 Phase Ib/II Fresolimumab SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Recruiting
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Active, not recruiting
NCT02584634 Phase I Crizotinib Avelumab Lorlatinib Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Active, not recruiting
NCT02588261 Phase III Naquotinib Gefitinib Erlotinib A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations Terminated
NCT02589522 Phase I Berzosertib VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Recruiting
NCT02591615 Phase II Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Active, not recruiting
NCT02592577 Phase I MAGE A10c796T for Advanced NSCLC Active, not recruiting
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting
NCT02595944 Phase III Nivolumab Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) Active, not recruiting
NCT02599454 Phase I Atezolizumab Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Active, not recruiting
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting
NCT02609776 Phase I JNJ-61186372 Carboplatin + JNJ-61186372 + Pemetrexed Disodium JNJ-61186372 + Lazertinib Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) Recruiting
NCT02616393 Phase II Tesevatinib Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases Completed
NCT02621398 Phase I Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02630186 Phase Ib/II Atezolizumab + Rociletinib A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC Terminated
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02635061 Phase I Citarinostat + Ipilimumab + Nivolumab Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer Active, not recruiting
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Active, not recruiting
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Active, not recruiting
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Disodium Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Completed
NCT02639234 Phase II FANG vaccine + Nivolumab Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer Withdrawn
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Active, not recruiting
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Active, not recruiting
NCT02642939 Phase II Mifepristone Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Active, not recruiting
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02654587 Phase III OSE 2101 Pemetrexed Disodium Docetaxel Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) Recruiting
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Recruiting
NCT02659059 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Active, not recruiting
NCT02664181 Phase II Nivolumab Decitabine + Nivolumab + Tetrahydrouridine Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) Completed
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed
NCT02666105 Phase II Exemestane Exemestane in Post-Menopausal Women With NSCLC Recruiting
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Recruiting
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Active, not recruiting
NCT02695290 Phase III Afatinib Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated
NCT02696993 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer Recruiting
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Recruiting
NCT02706626 Phase II Brigatinib Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Recruiting
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Active, not recruiting
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed
NCT02713828 Phase Ib/II Glembatumumab vedotin Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Terminated
NCT02713867 Phase III Nivolumab A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) Active, not recruiting
NCT02715284 Phase I Dostarlimab A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting
NCT02716038 Phase II Atezolizumab + Carboplatin + Nab-paclitaxel Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Active, not recruiting
NCT02716116 Phase Ib/II AP32788 A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02730247 Phase II Nab-paclitaxel + Ramucirumab Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed
NCT02733250 Phase Ib/II Nab-paclitaxel + Pembrolizumab Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) Active, not recruiting
NCT02737501 Phase III Brigatinib Crizotinib ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L) Active, not recruiting
NCT02740985 Phase I AZD4635 AZD4635 + Durvalumab A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies Recruiting
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting
NCT02750514 Phase II Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab BMS-986205 + Nivolumab An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) Active, not recruiting
NCT02767804 Phase III Crizotinib Ensartinib eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting
NCT02768558 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC Terminated
NCT02770014 Phase II Erlotinib Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Terminated
NCT02775435 Phase III Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Active, not recruiting
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Active, not recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Recruiting
NCT02784158 Phase I Brigatinib An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available
NCT02789345 Phase I Osimertinib + Ramucirumab Necitumumab + Osimertinib A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Active, not recruiting
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02803203 Phase Ib/II Bevacizumab + Osimertinib Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers Active, not recruiting
NCT02805660 Phase Ib/II Durvalumab + Mocetinostat Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Completed
NCT02812667 Phase I Nivolumab + Plinabulin Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting
NCT02823990 Phase II MVA-MUC1-IL2 vaccine + Nivolumab TG4010 and Nivolumab in Patients With Lung Cancer Active, not recruiting
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed
NCT02826161 Phase III Napabucasin + Paclitaxel Paclitaxel A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) Terminated
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Active, not recruiting
NCT02831491 Phase II Docetaxel + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Withdrawn
NCT02831933 Phase II AdV-tk + Nivolumab Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) Recruiting
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Completed
NCT02846792 Phase Ib/II Nivolumab + Plinabulin Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Terminated
NCT02848651 Phase II Atezolizumab A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] Completed
NCT02855125 Phase II Tegafur-gimeracil-oteracil Potassium TAS-114 + Tegafur-gimeracil-oteracil Potassium A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Completed
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed
NCT02864251 Phase III Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) Recruiting
NCT02869789 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Active, not recruiting
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Recruiting
NCT02879760 Phase Ib/II Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients Active, not recruiting
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Completed
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Recruiting
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Recruiting
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed
NCT02898116 Phase Ib/II Durvalumab + Ensartinib Ensartinib A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer Completed
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Active, not recruiting
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Recruiting
NCT02912949 Phase Ib/II Zenocutuzumab A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Recruiting
NCT02917993 Phase Ib/II Itacitinib + Osimertinib An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Active, not recruiting
NCT02919449 Phase I Atezolizumab + MV-NIS Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer Terminated
NCT02920450 Phase Ib/II Carboplatin + Gedatolisib + Paclitaxel Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) Terminated
NCT02920996 Phase II Merestinib Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Active, not recruiting
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02922777 Phase I Bemcentinib + Docetaxel Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT02926768 Phase Ib/II CK-101 Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Active, not recruiting
NCT02927301 Phase II Atezolizumab A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT02927340 Phase II Lorlatinib A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions Recruiting
NCT02941601 Phase II Carboplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Active, not recruiting
NCT02944396 Phase II Carboplatin + Paclitaxel + Pemetrexed Disodium + Veliparib Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Veliparib Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) Completed
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02947386 Phase Ib/II Nimotuzumab + Nivolumab Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Recruiting
NCT02949843 Phase II Nivolumab + Pembrolizumab Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Active, not recruiting
NCT02950038 Phase II Ibrutinib + Nivolumab Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Active, not recruiting
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT02952989 Phase I SGN-2FF A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Terminated
NCT02954523 Phase Ib/II Dasatinib + Osimertinib Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Active, not recruiting
NCT02954991 Phase II MGCD516 + Nivolumab Mocetinostat + Nivolumab Glesatinib + Nivolumab Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Recruiting
NCT02955290 Phase Ib/II CIMAvax-EGF + Nivolumab CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Completed
NCT02963610 Phase Ib/II Lenalidomide + Pembrolizumab Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Terminated
NCT02965885 Phase I Pimitespib A Study of TAS-116 in Patients With Solid Tumors Completed
NCT02967133 Phase II Nab-paclitaxel + Nivolumab Nivolumab A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Active, not recruiting
NCT02971501 Phase II Osimertinib Bevacizumab + Osimertinib Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases Active, not recruiting
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Recruiting
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Active, not recruiting
NCT02981108 Phase Ib/II Almonertinib A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Unknown status
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Active, not recruiting
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting
NCT02987998 Phase I Cisplatin + Etoposide + Pembrolizumab Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Active, not recruiting
NCT02991651 Phase I Erlotinib + IRX4204 Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC Unknown status
NCT02998528 Phase III Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Active, not recruiting
NCT03001882 Phase II Ipilimumab + Nivolumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03003468 Phase Ib/II Pembrolizumab + PGG beta-glucan Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 Recruiting
NCT03003962 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Active, not recruiting
NCT03004105 Phase II Durvalumab + Selumetinib MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Withdrawn
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting
NCT03014648 Phase II Atezolizumab Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03023423 Phase Ib/II Atezolizumab + Daratumumab Atezolizumab A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) Completed
NCT03023904 Phase II Nivolumab Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Withdrawn
NCT03037385 Phase Ib/II BLU-667 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Recruiting
NCT03041181 Phase II Docetaxel + Nivolumab Docetaxel Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab Terminated
NCT03042013 Phase II Naquotinib A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study Withdrawn
NCT03048136 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn
NCT03048500 Phase II Metformin + Nivolumab Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Recruiting
NCT03049618 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Recruiting
NCT03050060 Phase II Nelfinavir + Nivolumab Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Suspended
NCT03050554 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT03052608 Phase III Lorlatinib Crizotinib A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Recruiting
NCT03054038 Phase I Afatinib + Necitumumab Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Recruiting
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting
NCT03064854 Phase I Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Active, not recruiting
NCT03066206 Phase II Poziotinib Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Recruiting
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status
NCT03082300 Phase I Naquotinib A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations Terminated
NCT03083808 Phase II Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Phase II Trial of Continuation Therapy in Advanced NSCLC Recruiting
NCT03086733 Phase II Metformin Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) Recruiting
NCT03087448 Phase Ib/II Ceritinib + Trametinib Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Recruiting
NCT03088930 Phase II Crizotinib Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Recruiting
NCT03090737 Phase II Nivolumab Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) Active, not recruiting
NCT03093116 Phase Ib/II Repotrectinib A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting
NCT03095612 Phase Ib/II Docetaxel + Selinexor Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Active, not recruiting
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Recruiting
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Completed
NCT03102242 Phase II Atezolizumab Atezolizumab Immunotherapy in Patients With Advanced NSCLC Active, not recruiting
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Active, not recruiting
NCT03110978 Phase II Nivolumab Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR Recruiting
NCT03121417 Phase II Nivolumab Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer Withdrawn
NCT03122717 Phase I Gefitinib + Osimertinib Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Recruiting
NCT03123783 Phase Ib/II APX005M + Nivolumab CD40 Agonistic Antibody APX005M in Combination With Nivolumab Recruiting
NCT03130764 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC Withdrawn
NCT03131037 Phase I AdV-tk + Valacyclovir Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer Active, not recruiting
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03137771 Phase II Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT03138889 Phase I NKTR-214 + Pembrolizumab A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL) Recruiting
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Recruiting
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Recruiting
NCT03156114 Phase I BI 754091 BI 754111 This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Recruiting
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Recruiting
NCT03158883 Phase I Avelumab UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Recruiting
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Active, not recruiting
NCT03164772 Phase Ib/II BI 1361849 + Durvalumab + Tremelimumab Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC Recruiting
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn
NCT03166631 Phase I BI 754091 + BI 891065 BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Recruiting
NCT03168464 Phase Ib/II Nivolumab Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Active, not recruiting
NCT03170206 Phase Ib/II Palbociclib Binimetinib Binimetinib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Recruiting
NCT03175224 Phase Ib/II Bozitinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting
NCT03177291 Phase I Carboplatin + Pemetrexed Disodium + Pirfenidone Carboplatin + Paclitaxel + Pirfenidone Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Recruiting
NCT03178071 Expanded access Lorlatinib Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations No longer available
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting
NCT03179436 Phase Ib/II MK-1308 + Pembrolizumab MK-1308 Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Recruiting
NCT03181308 Phase I Carotuximab + Nivolumab Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Completed
NCT03184571 Phase II Bemcentinib + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC Recruiting
NCT03191149 Phase II Osimertinib Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Suspended
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) Active, not recruiting
NCT03195491 Phase III Nivolumab A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) Active, not recruiting
NCT03202940 Phase Ib/II Alectinib + Cobimetinib A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Recruiting
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Active, not recruiting
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Recruiting
NCT03217669 Phase I Epacadostat + Sirolimus Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy Recruiting
NCT03220477 Phase I Guadecitabine + Mocetinostat + Pembrolizumab Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Recruiting
NCT03223155 Phase I Ipilimumab + Nivolumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Recruiting
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03228186 Phase II Docetaxel + MLN4924 Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Recruiting
NCT03228667 Phase II ALT-803 + Nivolumab ALT-803 + Pembrolizumab QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy Recruiting
NCT03232892 Phase II Trametinib Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer Terminated
NCT03233724 Phase Ib/II Pembrolizumab Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Recruiting
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Recruiting
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Recruiting
NCT03239340 Phase III Osimertinib A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib Active, not recruiting
NCT03242915 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease Recruiting
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Active, not recruiting
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Completed
NCT03257722 Phase Ib/II Idelalisib + Pembrolizumab Pembrolizumab + Idelalisib for Lung Cancer Study Recruiting
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Recruiting
NCT03262779 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Recruiting
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Active, not recruiting
NCT03268057 Phase Ib/II Avelumab + Pepinemab VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer Active, not recruiting
NCT03270176 Phase I Avelumab + Debio 1143 A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy Recruiting
NCT03274479 Phase I PBF-1129 PBF-1129 in Patients With NSCLC Recruiting
NCT03275597 Phase I Durvalumab + Tremelimumab Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Recruiting
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03286296 Phase I LZM009 LZM009 to Treat Patients With Advanced Solid Tumors Completed
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03292133 Phase II Gefitinib + Nazartinib A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT03299088 Phase I Pembrolizumab + Trametinib Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Recruiting
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Active, not recruiting
NCT03302247 Phase II Nivolumab Gemcitabine + Nivolumab Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy Terminated
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Recruiting
NCT03308942 Phase II Niraparib Niraparib + Pembrolizumab Dostarlimab + Niraparib Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Active, not recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Withdrawn
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Recruiting
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Recruiting
NCT03318939 Phase II Poziotinib Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Recruiting
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Recruiting
NCT03322540 Phase II Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) Active, not recruiting
NCT03322566 Phase II Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) Active, not recruiting
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Recruiting
NCT03326752 Phase I DV281 Phase 1b Dose Escalation and Dose Expansion Trial Completed
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Active, not recruiting
NCT03333343 Phase I LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC Recruiting
NCT03334617 Phase II AZD9150 + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan AZD6738 + Durvalumab Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) Recruiting
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + CPI-444 Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Recruiting
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated
NCT03348904 Phase III Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer Terminated
NCT03353675 Phase II MVA-MUC1-IL2 vaccine + Nivolumab A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated
NCT03366766 Phase II Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery Active, not recruiting
NCT03367819 Phase Ib/II Isatuximab Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Active, not recruiting
NCT03371992 Phase I Nivolumab Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) Enrolling by invitation
NCT03377023 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Recruiting
NCT03380871 Phase I Carboplatin + NEO-PV-01 + Pembrolizumab + Pemetrexed Disodium + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Active, not recruiting
NCT03381274 Phase Ib/II AZD4635 + Oleclumab Oleclumab + Osimertinib MEDI9447 EGFRm NSCLC Novel Combination Study Active, not recruiting
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Terminated
NCT03382912 Phase II Nivolumab + Pegilodecakin Nivolumab Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) Terminated
NCT03386929 Phase Ib/II Avelumab + Axitinib + Palbociclib Survival Prolongation by Rationale Innovative Genomics (SPRING) Active, not recruiting
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Active, not recruiting
NCT03391869 Phase III Ipilimumab + Nivolumab Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR) Recruiting
NCT03392246 Phase II Osimertinib + Selumetinib A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Recruiting
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Active, not recruiting
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Active, not recruiting
NCT03401385 Phase I DS-1062a First-in-human Study of DS-1062a for Advanced Solid Tumors Recruiting
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03409614 Phase III Cemiplimab + Ipilimumab Cemiplimab REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Recruiting
NCT03410043 Phase II Osimertinib Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting
NCT03417037 Phase III BMS-986205 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer Withdrawn
NCT03417882 Phase II GRN-1201 + Pembrolizumab GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Recruiting
NCT03418532 Phase Ib/II MP0250 MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC Terminated
NCT03419559 Phase II LN-145 Durvalumab + LN-145 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer Withdrawn
NCT03425006 Phase II Itacitinib + Pembrolizumab Pembrolizumab and Itacitinib (INCB039110) for NSCLC Active, not recruiting
NCT03425279 Phase Ib/II CAB-AXL-ADC CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03425331 Phase II Ipilimumab + Nivolumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Suspended
NCT03425643 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Recruiting
NCT03430063 Phase II Cemiplimab + Ipilimumab Cemiplimab A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer Active, not recruiting
NCT03433469 Phase II Osimertinib Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Recruiting
NCT03434418 Phase II Osimertinib A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Recruiting
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Recruiting
NCT03438318 Phase I Atezolizumab + QbG10 Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer Completed
NCT03446417 Phase I ZN-e4 A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer Recruiting
NCT03447769 Phase III Canakinumab Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03455556 Phase Ib/II Anetumab ravtansine + Atezolizumab Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer Terminated
NCT03455829 Phase Ib/II Osimertinib G1T38 + Osimertinib G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Active, not recruiting
NCT03456063 Phase III Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Recruiting
NCT03456076 Phase III Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Recruiting
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Active, not recruiting
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Active, not recruiting
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Active, not recruiting
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03502330 Phase I APX005M + Cabiralizumab + Nivolumab APX005M + Cabiralizumab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Recruiting
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03505710 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Recruiting
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Active, not recruiting
NCT03515629 Phase III Cemiplimab + Ipilimumab Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Active, not recruiting
NCT03515837 Phase III Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cisplatin + Pemetrexed Disodium Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) Active, not recruiting
NCT03516981 Phase II MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03520686 Phase III ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. Recruiting
NCT03520842 Phase II Methotrexate + Regorafenib Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Recruiting
NCT03521154 Phase III Osimertinib A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) Recruiting
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Active, not recruiting
NCT03527108 Phase II Nivolumab + Ramucirumab Nivolumab Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Not yet recruiting
NCT03535363 Phase I Osimertinib Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC Recruiting
NCT03535740 Phase II Brigatinib A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib Active, not recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer Recruiting
NCT03546361 Phase I Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC Recruiting
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Recruiting
NCT03563716 Phase II Atezolizumab + MTIG7192A Atezolizumab A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03567642 Phase I Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Active, not recruiting
NCT03573947 Phase II Ipilimumab + Nivolumab + Paclitaxel Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) Recruiting
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Withdrawn
NCT03574649 Phase II Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Withdrawn
NCT03580694 Phase I Cemiplimab + REGN4659 Cemiplimab Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated
NCT03581487 Phase Ib/II Durvalumab + Selumetinib + Tremelimumab Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Recruiting
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Recruiting
NCT03586453 Phase II Osimertinib Osimertinib In EGFR Mutant Lung Cancer Recruiting
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Recruiting
NCT03590054 Phase I Abexinostat + Pembrolizumab A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Active, not recruiting
NCT03596866 Phase III Brigatinib Alectinib An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3) Recruiting
NCT03600701 Phase II Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03611738 Phase I Ceritinib + Docetaxel Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03625323 Phase II Eftilagimod alpha + Pembrolizumab Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) Recruiting
NCT03626545 Phase III Canakinumab + Docetaxel Docetaxel Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2) Active, not recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Active, not recruiting
NCT03631706 Phase II M7824 Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03631784 Phase II Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799) Active, not recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Active, not recruiting
NCT03634241 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules Recruiting
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Recruiting
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Recruiting
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Recruiting
NCT03645928 Phase II LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Recruiting
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting
NCT03647488 Phase II Capmatinib + Spartalizumab Docetaxel Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Active, not recruiting
NCT03656627 Phase I Nivolumab Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Recruiting
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03663166 Phase Ib/II Cisplatin + Ipilimumab + Pemetrexed Disodium Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03664024 Phase II Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) Active, not recruiting
NCT03665129 Phase I Durvalumab + IPH5401 IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Recruiting
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Recruiting
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03667820 Phase II Osimertinib Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03674827 Phase I PF-06936308 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC Recruiting
NCT03679767 Phase II Retifanlimab A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Recruiting
NCT03681483 Phase I RO5126766 RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated
NCT03689855 Phase II Atezolizumab + Ramucirumab Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1) Recruiting
NCT03693300 Phase II Durvalumab A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Recruiting
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Recruiting
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated
NCT03707938 Phase I Brigatinib Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Recruiting
NCT03708328 Phase I RO7121661 A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Recruiting
NCT03709706 Phase Ib/II NY-ESO-1-c259T + Pembrolizumab NY-ESO-1-c259T Pilot Immunotherapy Study With Autologous T-cells Specific for NY-ESO-1/ LAGE-1a-positive Advanced NSCLC Either Alone or in Combination With Pembrolizumab Recruiting
NCT03713944 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Recruiting
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Recruiting
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03737994 Phase II Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Recruiting
NCT03739710 Phase Ib/II Docetaxel Docetaxel + GSK3359609 Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03745222 Phase III Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Terminated
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03755102 Phase I Dacomitinib A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03769103 Phase II Osimertinib Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Recruiting
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Withdrawn
NCT03775486 Phase II Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) Active, not recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03778229 Phase II Osimertinib + Savolitinib Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) Recruiting
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Recruiting
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Active, not recruiting
NCT03793179 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Recruiting
NCT03794544 Phase II Durvalumab + Oleclumab AZD9150 + Durvalumab Durvalumab Durvalumab + Monalizumab Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Recruiting
NCT03797391 Phase Ib/II EMB-01 A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors Recruiting
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Gemcitabine A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Recruiting
NCT03801902 Phase I Durvalumab Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer Recruiting
NCT03805841 Phase II Tarloxotinib Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) Recruiting
NCT03808558 Phase II TVB-2640 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Recruiting
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB) Recruiting
NCT03810807 Phase I Dacomitinib + Osimertinib Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Recruiting
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer Recruiting
NCT03818776 Phase I Durvalumab Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC Recruiting
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT03822351 Phase II Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) Active, not recruiting
NCT03829319 Phase III Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) Recruiting
NCT03829332 Phase III Pembrolizumab Lenvatinib + Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naive Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007) Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03831932 Phase Ib/II Osimertinib + Telaglenastat Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer Recruiting
NCT03833154 Phase III Durvalumab Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) Recruiting
NCT03836352 Phase II DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Recruiting
NCT03840902 Phase II Carboplatin + Paclitaxel M7824 Cisplatin + Etoposide Durvalumab Cisplatin + Etoposide + M7824 Carboplatin + M7824 + Paclitaxel Cisplatin + M7824 + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03840915 Phase Ib/II Cisplatin + M7824 + Pemetrexed Disodium Docetaxel + M7824 Carboplatin + M7824 + Pemetrexed Disodium Cisplatin + Gemcitabine + M7824 Carboplatin + Gemcitabine + M7824 Carboplatin + M7824 + Nab-paclitaxel M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03845166 Phase I XL092 A Study of XL092 in Subjects With Solid Tumors Recruiting
NCT03845296 Phase II Rucaparib Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Recruiting
NCT03846310 Phase I AB928 + Carboplatin + Pemetrexed Disodium GLS-010 AB928 + Carboplatin + Pembrolizumab + Pemetrexed Disodium A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Recruiting
NCT03847519 Phase Ib/II ADXS-503 + Pembrolizumab ADXS-503 Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03867175 Phase III Pembrolizumab Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT03891615 Phase I Niraparib + Osimertinib Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Recruiting
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Recruiting
NCT03893955 Phase I ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 ABBV-181 + ABBV-927 + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03904108 Phase II Ramucirumab Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy Recruiting
NCT03915951 Phase II Binimetinib + Encorafenib An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer Recruiting
NCT03916419 Phase II Durvalumab Carboplatin + Paclitaxel Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer Active, not recruiting
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Recruiting
NCT03920839 Phase I Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Withdrawn
NCT03924869 Phase III Pembrolizumab Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) Recruiting
NCT03934814 Phase I TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03940703 Phase II Osimertinib + Tepotinib Tepotinib A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC) (INSIGHT 2) (INSIGHT 2) Recruiting
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Recruiting
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Recruiting
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Recruiting
NCT03964233 Phase I BI 754091 + BI 754111 BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111 Recruiting
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Suspended
NCT03965689 Phase II Carboplatin + MLN4924 + Paclitaxel Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT03965845 Phase Ib/II Palbociclib + Telaglenastat A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Recruiting
NCT03968419 Phase II Canakinumab Pembrolizumab Canakinumab + Pembrolizumab This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) Recruiting
NCT03971474 Phase II Docetaxel + Gemcitabine + Pemetrexed Disodium Docetaxel + Ramucirumab Docetaxel + Gemcitabine Pembrolizumab + Ramucirumab Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Recruiting
NCT03973333 Phase Ib/II Atezolizumab + IMC-C103C IMC-C103C Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab Recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting
NCT03989362 Phase II Ipilimumab + Vopratelimab Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE) Recruiting
NCT03991819 Phase I Binimetinib + Pembrolizumab Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer Active, not recruiting
NCT03993873 Phase I TPX-0022 Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Recruiting
NCT03996473 Phase Ib/II Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases Recruiting
NCT03999710 Phase II Durvalumab Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Recruiting
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Recruiting
NCT04003246 Phase III Durvalumab Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer Recruiting
NCT04005144 Phase I Binimetinib + Brigatinib Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Recruiting
NCT04006301 Phase I JNJ-74699157 First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation Active, not recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting
NCT04013542 Phase I Ipilimumab + Nivolumab Nivolumab Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Active, not recruiting
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Recruiting
NCT04025879 Phase III Carboplatin + Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Recruiting
NCT04026412 Phase III Nivolumab Ipilimumab + Nivolumab Durvalumab A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Recruiting
NCT04032418 Phase II Pembrolizumab Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer Recruiting
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting
NCT04036682 Phase Ib/II CLN-081 A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Recruiting
NCT04037462 Phase Ib/II Dexamethasone Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy Not yet recruiting
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting
NCT04042701 Phase I Pembrolizumab + Trastuzumab deruxtecan DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Recruiting
NCT04044859 Phase I ADP-A2M4 cells Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting
NCT04061590 Phase II Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Not yet recruiting
NCT04062708 Phase II Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Not yet recruiting
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Recruiting
NCT04069936 Phase II Marrow infiltrating lymphocytes + Pembrolizumab Marrow infiltrating lymphocytes Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs - NSCLC) Alone or in Combination With Pembrolizumab in Advanced Unresectable or Metastatic NSCLC Recruiting
NCT04075396 Phase Ib/II Lazertinib A Study of YH25448 in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT04077099 Phase Ib/II REGN5093 REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Recruiting
NCT04077463 Phase I JNJ-61186372 + Lazertinib Lazertinib A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Participants With Advanced Non-small Cell Lung Cancer Recruiting
NCT04081688 Phase I Atezolizumab + Varlilumab Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC Recruiting
NCT04083599 Phase Ib/II GEN1042 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Recruiting
NCT04092283 Phase III Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Recruiting
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Recruiting
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Not yet recruiting
NCT04120454 Phase II Pembrolizumab + Ramucirumab Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Not yet recruiting
NCT04123379 Phase II BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Recruiting
NCT04129502 Phase III AP32788 Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Recruiting
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Recruiting
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting
NCT04141644 Phase I Ipilimumab + Osimertinib PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi) Recruiting
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Recruiting
NCT04146571 Expanded access Ensartinib Expanded Access to Ensartinib for Participants With ALK+ NSCLC Available
NCT04151563 Phase Ib/II Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy Not yet recruiting
NCT04157517 Phase I TAK-573 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study Recruiting
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn
NCT04165070 Phase II Carboplatin + MK-7684 + Pembrolizumab + Pemetrexed Disodium Carboplatin + MK-7684 + Paclitaxel + Pembrolizumab Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A) Recruiting
NCT04165096 Phase II MK-5890 + Pembrolizumab Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C) Recruiting
NCT04165330 Phase Ib/II Anlotinib + Nivolumab Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Recruiting
NCT04166487 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium Plasma-Adapted First-Line Pembro In NSCLC Recruiting
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Recruiting
NCT04173507 Phase II Avelumab + Talazoparib Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Recruiting
NCT04189614 Phase I Cofetuzumab pelidotin An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer Recruiting
NCT04197934 Phase I WSD0922 WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases Recruiting
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting
NCT04205812 Phase III Retifanlimab Pemetrexed Disodium Carboplatin + Nab-paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Nab-paclitaxel + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Retifanlimab Carboplatin + Paclitaxel Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) Recruiting
NCT04214262 Phase III Atezolizumab Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Recruiting
NCT04216316 Phase Ib/II Avelumab + Carboplatin + Gemcitabine Avelumab + Berzosertib + Carboplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatments (Carboplatin and Gemcitabine) and to Avelumab for Non-small Cell Lung Cancer Recruiting
NCT04219254 Phase Ib/II BI-1206 + Pembrolizumab A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT04222972 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium BLU-667 Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC Recruiting
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting
NCT04227028 Phase I Bevacizumab + Brigatinib Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer Recruiting
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Recruiting
NCT04249362 Phase II Durvalumab Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) Not yet recruiting
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting
NCT04253964 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy Recruiting
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Recruiting
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Not yet recruiting
NCT04262375 Phase II Durvalumab + Oleclumab A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) Not yet recruiting
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Not yet recruiting
NCT04262869 Phase II Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer Recruiting
NCT04267237 Phase II Atezolizumab + RO7198457 Atezolizumab A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer Recruiting
NCT04267848 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study Recruiting
NCT04268550 Phase II Selpercatinib Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Recruiting
NCT04272203 Phase I ABBV-184 A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers Recruiting
NCT04274907 Phase I Pembrolizumab + Venetoclax Pembrolizumab A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression Recruiting
NCT04285671 Phase Ib/II Necitumumab + Osimertinib + Trastuzumab Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Not yet recruiting
NCT04291105 Phase II Cemiplimab + VSV-hIFNbeta-NIS Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Recruiting
NCT04292119 Phase Ib/II Binimetinib + Lorlatinib Crizotinib + Lorlatinib Lorlatinib Combinations in Lung Cancer Recruiting
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting
NCT04294810 Phase III Atezolizumab Atezolizumab + MTIG7192A A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01) Recruiting
NCT04297605 Phase I Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 Not yet recruiting
NCT04302025 Phase II Cobimetinib + Vemurafenib Entrectinib Alectinib A Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Participants With Stages I-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, or BRAF v600E Molecular Alterations Recruiting
NCT04303780 Phase III AMG 510 Docetaxel Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). Recruiting
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Recruiting
NCT04310020 Phase II Atezolizumab Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients Recruiting
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Recruiting
NCT04314089 Phase I GT103 Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) Recruiting
NCT04317534 Phase II Pembrolizumab Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm Recruiting
NCT04330664 Phase Ib/II MRTX849 + TNO155 Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation Recruiting
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting
NCT04335292 Phase II Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Osimertinib Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT) Not yet recruiting
NCT04340882 Phase II Docetaxel + Pembrolizumab + Ramucirumab Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (TaxRamPem) Recruiting
NCT04348292 Phase I Durvalumab + Sirolimus Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer Recruiting
NCT04349267 Phase Ib/II BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors Recruiting
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Recruiting
NCT04364620 Phase II AB-16B5 + Docetaxel AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer Not yet recruiting
NCT04367311 Phase II Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Docetaxel Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Recruiting
NCT04372927 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Not yet recruiting
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Recruiting
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Recruiting
NCT04385368 Phase III Durvalumab Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) Recruiting
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting
NCT04396535 Phase II Docetaxel + M7824 Docetaxel Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer Not yet recruiting
NCT04410796 Phase II Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Recruiting
NCT04418167 Phase I JSI-1187 Dabrafenib + JSI-1187 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Recruiting
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting
NCT04441138 Phase II Durvalumab Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) Not yet recruiting
NCT04452214 Phase I Nidanilimab + Pembrolizumab A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors Not yet recruiting
NCT04467723 Phase Ib/II Atezolizumab + Pirfenidone Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC Not yet recruiting
NCT04467801 Phase II Ipatasertib Docetaxel + Ipatasertib Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Not yet recruiting
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. Not yet recruiting
NCT04471428 Phase III Docetaxel Atezolizumab + Cabozantinib Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01) Recruiting
NCT04479306 Phase I Osimertinib + Sapanisertib Alisertib + Osimertinib Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer Recruiting
NCT04487080 Phase III JNJ-61186372 + Lazertinib Lazertinib Osimertinib A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) Not yet recruiting
NCT04499053 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer Not yet recruiting
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Not yet recruiting